-
Abstract Number: PB1100
Vaccine Induced Immune Thrombocytopenia and Thrombosis (VITT) external quality assessment (EQA) scheme results and interpretations from a joint UKNEQAS BC, SSC and ECAT VITT Survey May 2021.
-
Abstract Number: PB0070
Vaccine Induced Thrombotic Thrombocytopenia post Dose 2 ChAdOx1 nCoV19 vaccination: less severe but not void of catastrophic outcomes
-
Abstract Number: VPB0135
Vaccine-induced thrombotic thrombocytopenia (VITT) in COVID-19 vaccination: Demystified
-
Abstract Number: OC 15.5
Validating Direct Oral Anticoagulants (DOAC) for Use in Children by the Throm-PED DOAC Registry of the International Pediatric Thrombosis Network
-
Abstract Number: OC 54.2
Validation of a Hospital-Acquired Venous Thrombosis Risk Assessment Model: The Medical Inpatient Thrombosis and Hemostasis (MITH) Study
-
Abstract Number: OC 24.2
VALIDATION OF A TREATMENT DECISION ALGORITHM FOR THE USE OF ANDEXANET ALFA IN ACUTE LIFE-THREATENING BLEEDING FROM DIRCT FACTOR Xa INHIBITORS
-
Abstract Number: PB1396
Validation of clinical reference ranges for viscoelastometric assessment of haemostasis (TEG® 6S) and standard laboratory tests in obstetric patients
-
Abstract Number: PO0073
Validation of DOAC Dipstick in obese patients anticoagulated with direct oral anticoagulants. Rationale and study design
-
Abstract Number: PB0246
Validation of Thai Pediatric Bleeding Assessment Tools Mobile Application for Diagnosis of Pediatric Bleeding Disorders
-
Abstract Number: PB0653
Validation of the Hemophilia Treatment Experience Measure (Hemo-TEM): a New Haemophilia-specific Patient-reported Outcome Measure
-
Abstract Number: PB0994
Validation of the IMPROVE Hospital-Acquired Bleeding Risk Assessment Model in The Medical Inpatients Thrombosis and Hemostasis Study (MITH) Population
-
Abstract Number: OC 54.3
Validation of the IMPROVE Hospital-Acquired Venous Thrombosis Risk Assessment Model in The Medical Inpatients Thrombosis and Hemostasis Study (MITH) Population
-
Abstract Number: PB0243
Validation of the PLTEMA10 in Cardiac Surgery (CS) neonatal population weighing less than 5 Kg
-
Abstract Number: PO0041
Value of rotational thrombelastometry in perioperative management of patients with inherited coagulopathy during surgery
-
Abstract Number: PB0949
Variability in thrombophilia testing in large international physician survey
-
Abstract Number: VPB0435
Vascular involvement in Behçet’s disease
-
Abstract Number: VPB0741
Vasculopathy as an Atypical Manifestation of Paroxysmal Nocturnal Hemoglobinuria: a Case Report
-
Abstract Number: VPB0634
Veno-occlusive disease in pediatric patients after stem cell transplant is associated with impaired fibrinolysis
-
Abstract Number: OC 25.1
Venous and Arterial Thromboembolism after Incident Colorectal Cancer in the Netherlands: Incidence, Predictors, and Prognosis
-
Abstract Number: OC 25.3
Venous thromboembolism and cancer. Incidence and sex difference.
-
Abstract Number: OC 42.4
Venous thromboembolism associated with oestrogen-containing contraceptives versus any hormonal risk factor: a comparison of recurrence rates
-
Abstract Number: OC 08.3
Venous thromboembolism in a large series of pediatric patients with acute lymphoblastic leukemia. Risk factors and use of prophylaxis.
-
Abstract Number: PB0937
Venous Thromboembolism in Bladder Cancer:Scope of the Problem and Patients’ Perspectives(VTE-BC)
-
Abstract Number: PB1323
Venous thromboembolism in obese patients: a ten-year experience
-
Abstract Number: PB1354
Venous Thromboembolism Prophylaxis Use by Pediatric Orthopedic Surgeons in Canada
-
Abstract Number: PB0454
Venous thromboembolism reoccurrence during factor Xa inhibitors in young patients associates with thoracic outlet syndrome and development of chronic thromboembolic pulmonary hypertension
-
Abstract Number: VPB1417
Venous thromboprophylaxis in 108 hospitalized pregnant women with COVID-19: Experience of a Public Hospital in Argentina from April 2020-July 2021.
-
Abstract Number: PB0956
Venous thrombosis associated with combined oral contraceptives: role of intrinsic thrombin generation potential
-
Abstract Number: PB0631
VhH anti-thrombomodulin clone 1 inhibits TAFI activation and enhances fibrinolysis in human whole blood under flow
-
Abstract Number: VPB0640
Vinegar Produce t-PA from Human Endothelial Cells
-
Abstract Number: PB0621
Virtually screening for novel small molecule inhibitors against the conformational landscape of coagulation factor XIII activation-path
-
Abstract Number: PB0473
Viscoelastic Testing to Guide Transfusion Management in Patients with End Stage Liver Disease: A Systematic Review and Meta-analysis
-
Abstract Number: PB0734
Visualization of Gliomas with Clot-binding Peptides
-
Abstract Number: VPB1313
VKORC1 -1639AA Genotype as a Possible Risk Factor for Venous Thromboembolism in Elderly Patients with FV Leiden Mutation
-
Abstract Number: OC 24.3
VMX-C001 is an effective factor Xa inhibitor reversal agent and displays a favorable pharmacodynamic profile in animal models
-
Abstract Number: PB0820
Von willebrand disease in older patients
-
Abstract Number: PB0299
Von Willebrand factor (VWF) multimer (MM) pattern in autoimmune thrombotic thrombocytopenic purpura (iTTP) during acute episodes and in remission
-
Abstract Number: PB0011
Von Willebrand factor levels at 3 months after endothelial injury in Acute Coronary Syndrome: Single center experience.
-
Abstract Number: VPB0842
von Willebrand factor multimer analysis may predict the development of transplant-associated thrombotic microangiopathy
-
Abstract Number: OC 46.4
von Willebrand Factor-targeting thrombolysis to overcome tissue Plasminogen Activator resistance in vivo
-
Abstract Number: VPB0836
VWD Connect Foundation Severe Von Willebrand Disease Patient Registry
ISTH 2022 Congress
July 9-13, 2022. London, England, UK.